<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02289196</url>
  </required_header>
  <id_info>
    <org_study_id>Vx-006-101</org_study_id>
    <nct_id>NCT02289196</nct_id>
  </id_info>
  <brief_title>Safety Study of Vx006 Vaccine in Solid Tumor Patients</brief_title>
  <official_title>A Multicenter, Open Label, Uncontrolled Phase I Trial to Compare Safety, Tolerability and Immunogenicity of Vx-006 Vaccine at 0.5mg, 1mg, 5mg and 10mg Doses in Human Leukocyte Antigen-A02 (HLA-A02) Positive Patients With Solid Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vaxon Biotech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vaxon Biotech</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with histologically proven malignancy with documented disease control (objective&#xD;
      response or stable disease) or Not Evaluable Disease (NED) expectancy &gt; 6 months; only&#xD;
      HLA-A*02 positive patients.&#xD;
&#xD;
      The primary objective of the trial is to compare safety and tolerability of four different&#xD;
      doses of Vx-006. The secondary objective is to compare immunogenicity of four different doses&#xD;
      of the Vx-006.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse event number by treatment group as a measure of safety and tolerability</measure>
    <time_frame>18 Weeks</time_frame>
    <description>The following parameters of safety and tolerability will be assessed:&#xD;
Physical examination and vital signs (blood pressure, pulse rate, body temperature, weight, height (only at baseline),&#xD;
Electrocardiogram,&#xD;
Adverse event evaluation,&#xD;
Eastern Cooperative Oncology Group (ECOG) performance status,&#xD;
Clinical laboratory evaluation: haematology and clinical chemistry&#xD;
Collection of concomitant medication</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune response evaluation by treatment group as a measure of efficacy</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Vx-006: 0,5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six injections of Vx-006 at 0,5 mg + Montanide ISA51™ will be administrated every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vx-006: 1mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six injections of Vx-006 at 1 mg + Montanide ISA51™ will be administrated every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vx-006: 5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six injections of Vx-006 at 5 mg + Montanide ISA51™ will be administrated every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vx-006: 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six injections of Vx-006 at 10 mg + Montanide ISA51™ will be administrated every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vx-006: 0,5mg</intervention_name>
    <arm_group_label>Vx-006: 0,5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vx-006: 1mg</intervention_name>
    <arm_group_label>Vx-006: 1mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vx-006: 5mg</intervention_name>
    <arm_group_label>Vx-006: 5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vx-006: 10mg</intervention_name>
    <arm_group_label>Vx-006: 10mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female &gt; or = 18 years of age;&#xD;
&#xD;
          2. Histologically proven malignancy;&#xD;
&#xD;
          3. Documented HLA-A*02 positivity, as determined by a central laboratory;&#xD;
&#xD;
          4. Disease control (Complete Response (CR), Partial Response (PR), or Stable Disease&#xD;
             (SD)) according to Response Evaluation Criteria In Solid Tumors (RECIST 1.1) criteria&#xD;
             or NED in the case of patients who received adjuvant chemotherapy&#xD;
&#xD;
          5. Patient with disease control or NED expectancy &gt; or = 6 months according to&#xD;
             investigator opinion;&#xD;
&#xD;
          6. ECOG performance status 0, 1;&#xD;
&#xD;
          7. Patients must have adequate renal and hepatic function as assessed by standard&#xD;
             laboratory criteria;&#xD;
&#xD;
          8. Patients must have adequate haematological function:&#xD;
&#xD;
               -  Platelet count &gt; or = 100 x 109/L;&#xD;
&#xD;
               -  White Blood Cell (WBC) count &gt; or = 2.5 x 109/L;&#xD;
&#xD;
               -  Haemoglobin &gt; or = 90g /L;&#xD;
&#xD;
          9. Female patients must be of non-child-bearing potential (i.e., women with functioning&#xD;
             ovaries who have a documented tubal ligation or hysterectomy, ovariectomy or women who&#xD;
             are post-menopausal). Women of child-bearing potential must have a negative urine&#xD;
             pregnancy test at baseline and agree to practice adequate contraception for 30 days&#xD;
             prior to administration of investigational product, throughout the study treatment&#xD;
             period and 30 days after completion of injections;&#xD;
&#xD;
         10. In the investigator's opinion, the patient is capable and willing to comply with the&#xD;
             requirements of the study;&#xD;
&#xD;
         11. Willing and able to sign a written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior treatment with cancer vaccines;&#xD;
&#xD;
          2. Treatment with immunotherapy (e.g., interferons, interleukins, Tumor Necrosis Factor&#xD;
             (TNF), or biological response modifiers, such as Granulocyte-Macrophage Colony&#xD;
             Stimulating Factor (GM-CSF) etc) within four weeks prior to the first vaccination;&#xD;
&#xD;
          3. Treatment with immunosuppressive agents (including corticosteroids) within 2 weeks&#xD;
             prior to the first vaccination;&#xD;
&#xD;
          4. Treatment with any investigational drugs, within 4 weeks prior to the first&#xD;
             vaccination;&#xD;
&#xD;
          5. Autoimmune or immunodeficiency disease that in the opinion of the investigator may&#xD;
             compromise the safety of the patient in the study;&#xD;
&#xD;
          6. Any pre-existing medical condition requiring concomitant systemic corticosteroid or&#xD;
             immunosuppressive therapy. The use of inhaled corticosteroids for Chronic Obstructive&#xD;
             Pulmonary Disease (COPD) or topical steroids is allowed;&#xD;
&#xD;
          7. Known hepatitis B and/or C infection documented in patient files, testing not&#xD;
             required;&#xD;
&#xD;
          8. Known HIV-positivity, testing not required;&#xD;
&#xD;
          9. Clinically significant hepatic dysfunction (Alanine amino transferase (ALT)&gt;2.5 times&#xD;
             normal upper limits [ULN], Aspartate Amino Transferase (AST)&gt;2.5 times Upper Limit of&#xD;
             Normal (ULN), bilirubin&gt;1.5 times ULN);&#xD;
&#xD;
         10. Clinically significant renal dysfunction (serum creatinine&gt;1.5 time ULN);&#xD;
&#xD;
         11. Uncontrolled congestive heart failure or hypertension, unstable heart disease&#xD;
             (coronary artery disease with unstable angina or myocardial infarction within 6 months&#xD;
             before enrolment) or uncontrolled ventricular arrhythmias at the time of enrolment in&#xD;
             the study (atrial fibrillation or flutter is acceptable);&#xD;
&#xD;
         12. Splenectomy or splenic irradiation;&#xD;
&#xD;
         13. Any infectious condition that, in the opinion of the investigator, could compromise&#xD;
             the patient's ability to develop an immune response;&#xD;
&#xD;
         14. Pregnant or lactating females (female patients of child-bearing potential will&#xD;
             undertake pregnancy testing at screening and during study completion/withdrawal&#xD;
             visits);&#xD;
&#xD;
         15. Alcohol or drug dependence;&#xD;
&#xD;
         16. Requirement of concurrent treatment with prohibited medication (investigational&#xD;
             product, other anti-cancer treatments including chemotherapy, non-palliative&#xD;
             radiotherapy, biological agents and immunomodulating agents, systemic&#xD;
             immunosuppressive agents, including systemic corticosteroids);&#xD;
&#xD;
         17. The investigator considers the patient unfit for the study as a result of the medical&#xD;
             interview, physical examination, or screening investigations.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katsaounis Panagiotis, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Iaso General Hospital, Athens</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>251 General Airforce Hospital</name>
      <address>
        <city>Athens</city>
        <zip>11525</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iaso General Hospital</name>
      <address>
        <city>Athens</city>
        <zip>15562</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Heraklion</name>
      <address>
        <city>Heraklion, Crete</city>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>October 30, 2014</study_first_submitted>
  <study_first_submitted_qc>November 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2014</study_first_posted>
  <last_update_submitted>June 18, 2019</last_update_submitted>
  <last_update_submitted_qc>June 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

